Hikma Pharmaceuticals Plc Stock Rating Reaffirmed by Jefferies Group (HIK)
Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “hold” rating reiterated by stock analysts at Jefferies Group in a report issued on Wednesday. They currently have a GBX 1,610 ($26.91) price target on the stock. Jefferies Group’s price target indicates a potential downside of 10.70% from the company’s current price.
Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1778.0001 on Wednesday. Hikma Pharmaceuticals Plc has a 52 week low of GBX 1004.00 and a 52 week high of GBX 1835.00. The stock’s 50-day moving average is GBX 1750. and its 200-day moving average is GBX 1599.. The company’s market cap is £3.516 billion.
A number of other firms have also recently commented on HIK. Analysts at Peel Hunt reiterated a “buy” rating on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday. They now have a GBX 1,850 ($30.93) price target on the stock. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday. They now have a GBX 1,580 ($26.41) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 14th. They now have a GBX 1,900 ($31.76) price target on the stock. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of GBX 1,802.50 ($30.13).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.